Recycling in the eye promotes good vision

Recycling in the eye promotes good vision
Recycling cellular debris within the eye is required for maintaining good vision. Inside retinal pigment epithelium cells, structures used for recycling (green) engulf and digest spent parts of photoreceptor cells (red).

Recycling isn't just good for the environment. It's also good for your eyesight.

Researchers at Washington University School of Medicine in St. Louis and St. Jude Children's Research Hospital in Memphis have found that good depends, at least in part, on a in the eye that mops up cellular debris and reuses light-.

The findings suggest that disruptions in that process may harm vision and play a key role in the development of eye diseases related to aging, including age-related macular degeneration, the leading cause of in Americans over 50. In the brain, similar defects in the recycling of proteins contribute to other disorders associated with aging, such as Alzheimer's and Parkinson's diseases, both of which are linked to the build up and aggregation of proteins in .

The study is published online in the journal Cell.

"One possibility is that as we age, these recycling pathways can become less efficient and the system becomes clogged," said co-senior author Thomas A. Ferguson, PhD, a professor of ophthalmology and visual sciences at Washington University. "That can cut down on the retina's ability to use vitamin A, which is crucial to good vision. Inefficient recycling also is thought to contribute to disorders like Alzheimer's, where patients can't clear proteins from the brain as they get older."

Working in mice, Ferguson and co-senior author Douglas R. Green, PhD, the Peter C. Doherty Endowed Professor Immunology at St. Jude, showed that vision suffers when the retina can't clear away debris produced by light-sensing .

The retina, located at the back of the eye, is populated with photoreceptors that absorb light and send to the brain, allowing us to see. A key component of these photoreceptors is a light-sensitive molecule called rhodopsin. It is rhodopsin that absorbs light, but each rhodopsin molecule only works for a brief stint. Once it has been exposed to light, rhodopsin breaks down and must be recycled to use again.

"After rhodopsin absorbs light, it's no good anymore," said Ferguson. "But the 'spent' rhodopsin is recharged through a series of chemical reactions so that the whole process can start all over again."

The key player in getting the rhodopsin recharged is a single layer of cells at the back of the retina called the epithelium (RPE), which recycles and recharges a molecule that rhodopsin needs to activate the photoreceptor cells.

In addition, the photoreceptor cells themselves also get a little ragged after repeated exposure to light and they, too, are continually shed and renewed each day.

In this new study, Ferguson and Green found that both the recycling of rhodopsin and the clearance of discarded bits of photoreceptors are initiated by a mechanism called autophagy.

"Autophagy is just what it sounds like: self-eating," said Green, the chair of immunology at St. Jude. "Under adverse conditions, cells digest their own internal structures. They essentially eat themselves to survive. The process we've studied shares features of autophagy, but also is distinct, and that's very exciting."

There is increasing evidence that when operating efficiently, autophagy can help stave off the cellular damage that occurs in age-related diseases such as Alzheimer's, and Ferguson and his colleagues suspect it also may play a role in age-related eye diseases.

But autophagy isn't the only mechanism at work in the retina. The retinal pigment epithelium (RPE) also uses a second eating process called phagocytosis to clear away parts of the photoreceptor cells that are constantly shed in the retina.

But it turns out that both autophagy—when cells eat themselves—and phagocytosis—when cells eat structures other than themselves—operate through the same pathway, the research shows.

To understand how those two mechanisms operate in the eye, Ferguson and Green studied mice. In the animals, as in people, photoreceptor discs are shed early each morning. The researchers found that signs of autophagy were visible in the mouse retina throughout the day but peaked at about 7 a.m.

Next, they generated mice whose retinal pigment epithelial cells lacked a gene essential for autophagy.

"One of the first things we noticed was that disrupting this unusual form of autophagy also disrupted the process of phagocytosis," Green explained. "The retinal pigment epithelium cells weren't able to digest debris from photoreceptors, suggesting that the two mechanisms shared a common pathway in the retina."

They also found that when the pathway was interrupted, the mice didn't see very well. Using complex techniques to measure vision, the researchers discovered that although the mice weren't losing photoreceptor cells, they were losing their vision.

"Their vision was reduced by 30 to 40 percent," Ferguson said. "But when we gave each of the mice a single injection of a molecule to restore the rhodopsin in their photoreceptors, their vision was restored to normal for several days."

The experiments, Ferguson said, suggested that autophagy assists the visual cycle by helping cells recover vitamin A, which is essential for the recycling of rhodopsin in the photoreceptors.

"And that is very interesting because deficiencies in vitamin A are known to lead to night blindness and other vision problems," he said. "We can't really say these mice were 'night blind,' but their vision was reduced because they couldn't efficiently recover enough vitamin A to restore rhodopsin to the ."

If that same process were to break down in humans as a function of aging, Ferguson believes it could play a role in the vision loss associated with normal aging and with diseases like macular degeneration.

"If autophagy becomes less efficient in the retina as a result of aging, it could cause problems clearing away debris and maintaining the visual cycle," he said.

Because previous studies have suggested autophagy can help clear harmful proteins that accumulate in cells during Alzheimer's and Parkinson's disease, new drugs are being developed to boost that recycling process. Ferguson and Green think some of those drugs may be useful in combating age-related vision loss.

More information: Cell vol. 153 (8), published online July 18, 2013.

Related Stories

Crag keeps the light 'fantastic' for photoreceptors

Dec 04, 2012

The ability of the eye of a fruit fly (Drosophila melanogaster) to respond to light depends on a delicate ballet that keeps the supply of light sensors called rhodopsin constant as photoreceptors turn on and off in respon ...

Altering eye cells may one day restore vision

Jan 25, 2013

(Medical Xpress)—Doctors may one day treat some forms of blindness by altering the genetic program of the light-sensing cells of the eye, according to scientists at Washington University School of Medicine ...

Photoreceptor transplant restores vision in mice

Apr 18, 2012

Scientists funded by the Medical Research Council (MRC) have shown for the first time that transplanting light-sensitive photoreceptors into the eyes of visually impaired mice can restore their vision.

Recommended for you

Multidose eye drop approach approved by joint commission

Dec 14, 2014

(HealthDay)—A policy and procedural approach to the use of multidose eye drops has been approved by The Joint Commission and can reduce costs for patients and facilities, according to an article published ...

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

Selluwud
5 / 5 (1) Jul 19, 2013
There are clinical trials being conducted as we speak by Advanced Cell Technology using retinal pigmented epithelium (RPE) derived from stem cells. These cells are injected sub-retinally and allowed to migrate into the fovea to rejuvenate dying and inactive photoreceptors. There so far is a 100% safety profile and it has been leaked and verified that one of the AMD trial patient's vision improved from 20/400 to 20/40....legally blind to being able to pass a driver test. Amazing stuff. The future of medicine is here right now.l
Selluwud
5 / 5 (1) Jul 19, 2013
May I add that the trials are FDA approved and being carried out at the very best top rated eye hospitals in the U.S. The SEC was bound by regulations to make ACT release a press statement about the improved vision patient after it was inadvertently spoken about in an interview with the chief science officer of the company, Dr. Lanza.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.